A catalogue of somatic NRF2 gain-of-function mutations in cancer
Open accessAbstract
Identification and characterization of somatic mutations in cancer have important prognostication and treatment implications. Genes encoding the Nuclear factor (erythroid-derived 2)-like 2 (NRF2) transcription factor and its negative regulator, Kelch-like ECH-associated protein 1 (KEAP1), are frequently mutated in cancer. These mutations drive constitutive NRF2 activation and correlate with poor prognosis. Despite its apparent significance, a comprehensive catalogue of somatic NRF2 mutations across different tumor types is still lacking. Here, we catalogue NRF2 mutations in The Cancer Genome Atlas (TCGA) database. 226 unique NRF2-mutant tumors were identified from 10,364 cases. NRF2 mutations were found in 21 out of the 33 tumor types. A total of 11 hotspots were identified. Of these, mutation to the R34 position was most frequent. Notably, R34 and D29 mutations were overrepresented in bladder, lung, and uterine cancers. Analyses of corresponding RNA sequencing data using a de novo derived gene expression classifier showed that the R34 mutations drive constitutive NRF2 activation with a selection pressure biased against the formation of R34L. Of all R34 mutants, R34L conferred the least degree of protein stabilization, suggesting a pro-tumor NRF2 half-life threshold. Our findings offer a comprehensive catalogue of NRF2 mutations in cancer that can help prognostication and NRF2 research.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Some somatic mutations give rise to hyperactive Nrf2, which causes enhanced antioxidant capacity and confers protection of cancer cells from ROS and cancer therapy, leading to cancer cell growth and proliferation, cancer progression, and cancer therapy resistance.
“Some somatic mutations give rise to hyperactive Nrf2, which causes enhanced antioxidant capacity and confers protection of cancer cells from ROS and cancer therapy, thereby leading to cancer cell growth and proliferation, cancer progression, and cancer therapy resistance (e.g., chemoresistance) (Figure 8) [161,162,163,164,165,166,167,168,169,170,171].”
From Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease (2022) · cites this paper as [168]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · see citing works
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · see citing works
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999 · see citing works
Journal of Statistical Software
de Leeuw, J. (2009) · Wiley Interdisciplinary Reviews Computational Statistics · doi:10.1002/wics.10 · Cited by 3,608 · see citing works
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096 · see citing works
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,800 · see citing works
Dinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., & Talalay, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398899 · Cited by 1,947 · see citing works
Nrf2–Keap1 defines a physiologically important stress response mechanism
Motohashi, H., & Yamamoto, M. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.09.003 · Cited by 1,725 · see citing works
Zhang, D. D., & Hannink, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.22.8137-8151.2003 · Cited by 1,480 · see citing works
Rcpp : Seamless R and C++ Integration
Eddelbuettel, D., & François, R. (2011) · Journal of Statistical Software · doi:10.18637/jss.v040.i08 · Cited by 1,403 · see citing works
The emerging role of the Nrf2–Keap1 signaling pathway in cancerPreprint
Jaramillo, M. C., & Zhang, D. D. (2013) · Genes & Development · doi:10.1101/gad.225680.113 · Cited by 1,304 · see citing works
NRF2 and cancer: the good, the bad and the importance of context
Sporn, M. B., & Liby, K. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3278 · Cited by 1,067 · see citing works
Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060 · see citing works
Molecular basis of the Keap1–Nrf2 system
Suzuki, T., & Yamamoto, M. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.006 · Cited by 995 · see citing works
NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer
Hayes, J. D., & McMahon, M. J. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.12.008 · Cited by 870 · see citing works
Preventable Exposures Associated With Human Cancers
Cogliano, V. J., Baan, R. A., Straíf, K., Grosse, Y., Secretan, B., Ghissassi, F. E., Bouvard, V., Benbrahim‐Tallaa, L., Guha, N., Freeman, C., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr483 · Cited by 826 · see citing works
Polycyclic Aromatic Hydrocarbons: From Metabolism to Lung Cancer
Moorthy, B., Chu, C., & Carlin, D. J. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv040 · Cited by 807 · see citing works
Tong, K. I., Katoh, Y., Kusunoki, H., Itoh, K., Tanaka, T., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.2887-2900.2006 · Cited by 759 · see citing works
Furukawa, M., & Xiong, Y. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.25.1.162-171.2005 · Cited by 746 · see citing works
Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer
Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.-I., Kobayashi, A., Yokoyama, S., & Yamamoto, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.013 · Cited by 735 · see citing works
Shibata, T., Ohta, T., Tong, K. I., Kokubu, A., Odogawa, R., Tsuta, K., Asamura, H., Yamamoto, M., & Hirohashi, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806268105 · Cited by 728 · see citing works
Adam, J., Hatipoglu, E., O'Flaherty, L., Ternette, N., Sahgal, N., Lockstone, H., Baban, D., Nye, E., Stamp, G. W., Wolhuter, K., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.006 · Cited by 585 · see citing works
Characterization of NEDD8, a Developmentally Down-regulated Ubiquitin-like Protein
Kamitani, T., Kito, K., Nguyen, H. P., & Yeh, E. T. H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.45.28557 · Cited by 535 · see citing works
Formation and Biological Targets of Quinones: Cytotoxic versus Cytoprotective Effects
Bolton, J. L., & Dunlap, T. L. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00256 · Cited by 528 · see citing works
McMahon, M. J., Thomas, N., Itoh, K., Yamamoto, M. P., & Hayes, J. D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601119200 · Cited by 489 · see citing works
Tong, K. I., Padmanabhan, B., Kobayashi, A., Shang, C., Hirotsu, Y., Yokoyama, S., & Yamamoto, M. P. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00753-07 · Cited by 447 · see citing works
McMahon, M. J., Lamont, D. J., Beattie, K. A., & Hayes, J. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007387107 · Cited by 445 · see citing works
Nrf2–MafG heterodimers contribute globally to antioxidant and metabolic networks
Hirotsu, Y., Katsuoka, F., Funayama, R., Nagashima, T., Nishida, Y., Nakayama, K., Engel, J. D., & Yamamoto, M. P. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks827 · Cited by 431 · see citing works
Solis, L. M., Behrens, C., Dong, W., Suraokar, M. B., Ozburn, N. C., Moran, C. A., Corvalán, A. H., Biswal, S. S., Swisher, S. G., Bekele, B. N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3352 · Cited by 430 · see citing works
Ooi, A., Wong, J.-C., Petillo, D., Roossien, D., Perrier-Trudova, V., Whitten, D., Min, B. W. H., Tan, M.-H., Zhang, Z., Yang, X. J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.024 · Cited by 401 · see citing works
Self-citationFeng, Z., Hu, W., Hu, Y., & Tang, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607031103 · Cited by 374 · see citing works
Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin
Kim, Y. R., Oh, J. E., Kim, M. S., Kang, M. R., Park, S. W., Han, J. Y., Eom, H., Yoo, N. J., & Lee, S. H. (2009) · The Journal of Pathology · doi:10.1002/path.2653 · Cited by 357 · see citing works
Maher, J. M., Dieter, M. Z., Aleksunes, L. M., Slitt, A. L., Guo, G. L., Tanaka, Y., Scheffer, G. L., Chan, J. Y., Manautou, J. E., Chen, Y., et al. (2007) · Hepatology · doi:10.1002/hep.21831 · Cited by 315 · see citing works
Targeting NRF2 signaling for cancer chemoprevention
Kwak, M.-K., & Kensler, T. W. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.08.028 · Cited by 306 · see citing works
Fukumoto, S., Yamauchi, N., Moriguchi, H., Hippo, Y., Watanabe, A., Shibahara, J., Taniguchi, H., Ishikawa, S., Ito, H., Yamamoto, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1238 · Cited by 290 · see citing works
Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer
Konstantinopoulos, P. A., Spentzos, D., Fountzilas, E., Francoeur, N. J., Sanisetty, S., Grammatikos, A. P., Hecht, J. L., & Cannistra, S. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4668 · Cited by 272 · see citing works
Fukutomi, T., Takagi, K., Mizushima, T., Ohuchi, N., & Yamamoto, M. P. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01191-13 · Cited by 265 · see citing works
Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer
Bar-Peled, L., Kemper, E. K., Suciu, R. M., Vinogradova, E. V., Backus, K. M., Horning, B. D., Paul, T. A., Ichu, T.-A., Svensson, R. U., Olucha, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.051 · Cited by 262 · see citing works
Lee, J. H., Khor, T. O., Shu, L., Su, Z., Fuentes, F., & Kong, A. T. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.008 · Cited by 248 · see citing works
Shibata, T., Kokubu, A., Saito, S., Narisawa-Saito, M., Sasaki, H., Aoyagi, K., Yoshimatsu, Y., Tachimori, Y., Kushima, R., Kiyono, T., et al. (2011) · Neoplasia · doi:10.1593/neo.11750 · Cited by 224 · see citing works
Nrf2: control of sensitivity to carcinogens
Slocum, S. L., & Kensler, T. W. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0675-4 · Cited by 219 · see citing works
Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers
Goldstein, L. D., Lee, J., Gnad, F., Klijn, C. N., Schaub, A., Reeder, J., Daemen, A., Bakalarski, C. E., Holcomb, T., Shames, D. S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.010 · Cited by 200 · see citing works
Krøigård, A. B., Thomassen, M., Lænkholm, A., Kruse, T. A., & Larsen, M. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151664 · Cited by 180 · see citing works
Lu, K., Alcivar, A. L., Ma, J., Foo, T. K., Zywea, S., Mahdi, A., Huo, Y., Kensler, T. W., Gatza, M. L., & Xia, B. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2204 · Cited by 178 · see citing works
Ooi, A., Dykema, K., Ansari, A., Petillo, D., Snider, J., Kahnoski, R., Anema, J., Craig, D., Carpten, J., Teh, B.-T., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3227 · Cited by 159 · see citing works
Self-citationSmoking and cancer‐related gene expression in bronchial epithelium and non‐small‐cell lung cancers
Woenckhaus, M., Klein‐Hitpaß, L., Grepmeier, U., Merk, J., Pfeifer, R., Wild, P. J., Bettstetter, M., Wuensch, P. H., Blaszyk, H., Hartmann, A., et al. (2006) · The Journal of Pathology · doi:10.1002/path.2039 · Cited by 149 · see citing works
Targeting Nrf2 Signaling to Combat Chemoresistance
No, J. H., Kim, Y.-B., & Song, Y. S. (2014) · Journal of Cancer Prevention · doi:10.15430/jcp.2014.19.2.111 · Cited by 144 · see citing works
Cancer-Derived Mutations in KEAP1 Impair NRF2 Degradation but not Ubiquitination
Hast, B. E., Cloer, E. W., Goldfarb, D., Li, H., Siesser, P. F., Yan, F., Walter, V., Zheng, N., Hayes, D. N., & Major, M. B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1655 · Cited by 138 · see citing works
Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer
Muscarella, L. A., Parrella, P., D’Alessandro, V., la Torre, A., Barbano, R., Fontana, A., Tancredi, A., Guarnieri, V., Balsamo, T., Coco, M., et al. (2011) · Epigenetics · doi:10.4161/epi.6.6.15773 · Cited by 134 · see citing works
Cai, L., Yuan, W., Zhang, Z., He, L., & Chou, K. (2016) · Scientific Reports · doi:10.1038/srep36540 · Cited by 116 · see citing works
Namani, A., Rahaman, M. M., Chen, M., & Tang, X. (2018) · BMC Cancer · doi:10.1186/s12885-017-3907-z · Cited by 105 · see citing works
KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma
Li, Q. K., Singh, A., Biswal, S., Askin, F., & Gabrielson, E. (2011) · Journal of Human Genetics · doi:10.1038/jhg.2010.172 · Cited by 90 · see citing works
Nrf2 Overexpression Predicts Prognosis and 5-FU Resistance in Gastric Cancer
Hu, X., Yao, J., Gao, S., Wang, X., Peng, X.-Q., Yang, Y., & Feng, X. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.9.5231 · Cited by 82 · see citing works
Mutagenicity and Sequence Specificity of Acrolein-DNA Adducts
Wang, H., Zhang, S., Hu, Y., & Tang, M.-S. (2009) · Chemical Research in Toxicology · doi:10.1021/tx800369y · Cited by 79 · see citing works
Wang, J., Zhang, M., Zhang, L., Cai, H., Zhou, S., Zhang, J., & Wang, Y. (2010) · Journal of Surgical Research · doi:10.1016/j.jss.2010.05.058 · Cited by 75 · see citing works
Induction of the Keap1/Nrf2/ARE pathway by oxidizable diphenols
Dinkova‐Kostova, A. T., & Wang, X. J. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.09.010 · Cited by 70 · see citing works
MacLeod, A. K., Acosta-Jimenez, L., Coates, P. J., McMahon, M. J., Carey, F. A., Honda, T., Henderson, C. J., & Wolf, C. R. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.363 · Cited by 65 · see citing works
Dinkova‐Kostova, A. T. (2012) · Topics in current chemistry · doi:10.1007/128_2012_337 · Cited by 57 · see citing works
Nuclear factor, erythroid 2-like 2-associated molecular signature predicts lung cancer survival
Qian, Z., Zhou, T., Gurguis, C. I., Xu, X., Wen, Q., Lv, J., Fang, F., Hecker, L., Cress, A. E., Natarajan, V., et al. (2015) · Scientific Reports · doi:10.1038/srep16889 · Cited by 54 · see citing works
Orrù, C., Szydlowska, M., Taguchi, K., Zavattari, P., Perra, A., Yamamoto, M. P., & Columbano, A. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.010 · Cited by 38 · see citing works
MacLeod, A. K., Acosta-Jimenez, L., Coates, P. J., McMahon, M. J., Carey, F. A., Honda, T., Hayes, J. D., Henderson, C. J., & Wolf, C. R. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.80 · Cited by 36 · see citing works
Acrolein exposure suppresses antigen-induced pulmonary inflammation
Spiess, P. C., Kasahara, D. I., Habibovic, A., Hristova, M., Randall, M. J., Poynter, M. E., & van der Vliet, A. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-107 · Cited by 32 · see citing works
Genotoxicity of ortho-quinones: reactive oxygen species versus covalent modification
Penning, T. M. (2017) · Toxicology Research · doi:10.1039/c7tx00223h · Cited by 29 · see citing works
Sandhu, I. S., Maksim, N. J., Amouzougan, E. A., Gallion, B. W., Raviele, A. L. J., & Ooi, A. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150041 · Cited by 19 · see citing works
Self-citationActivation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro
Mine, N., Yamamoto, S., Kufe, D. W., Hoff, D. D. V., & Kawabe, T. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0808 · Cited by 11 · see citing works
Orrú, C., Szydlowska, M., Taguchi, K., Perra, A., Ledda, G. M., Yamamoto, M., & Columbano, A. (2018) · Journal of Hepatology · doi:10.1016/s0168-8278(18)30408-2 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,474 · see citing works
A compendium of mutational cancer driver genes
Martínez-Jiménez, F., Muiños, F., Sentís, I., Deu-Pons, J., Reyes-Salazar, I., Arnedo-Pac, C., Mularoni, L., Pich, O., Bonet, J., Kranas, H., et al. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0290-x · Cited by 1,278 · see citing works
Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease
Ngo, V., & Duennwald, M. L. (2022) · Antioxidants · doi:10.3390/antiox11122345 · Cited by 1,130 · see citing works
The multifaceted role of reactive oxygen species in tumorigenesis
Kirtonia, A., Sethi, G., & Garg, M. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03536-5 · Cited by 452 · see citing works
Short Overview of ROS as Cell Function Regulators and Their Implications in Therapy Concepts
Milković, L., Gašparović, A. Č., Cindrić, M., Mouthuy, P., & Žarković, N. (2019) · Cells · doi:10.3390/cells8080793 · Cited by 330 · see citing works
The KEAP1-NRF2 pathway: Targets for therapy and role in cancer
Adinolfi, S., Patinen, T., Deen, A. J., Pitkänen, S., Härkönen, J., Kansanen, E., Küblbeck, J., & Levonen, A. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102726 · Cited by 301 · see citing works
Oxidative Stress in the Tumor Microenvironment and Its Relevance to Cancer Immunotherapy
Aboelella, N. S., Brandle, C., Kim, T., Ding, Z., & Zhou, G. (2021) · Cancers · doi:10.3390/cancers13050986 · Cited by 295 · see citing works
Rauf, A., Khalil, A. A., Awadallah, S. M., Khan, S. A., Abu‐Izneid, T., Kamran, M., Hemeg, H. A., Mubarak, M. S., Khalid, A., & Wilairatana, P. (2023) · Food Science & Nutrition · doi:10.1002/fsn3.3784 · Cited by 201 · see citing works
The Nrf2 Pathway in Liver Diseases
Zhou, J., Zheng, Q., & Chen, Z. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.826204 · Cited by 196 · see citing works
NRF2: KEAPing Tumors Protected
Pillai, R., Hayashi, M., Zavitsanou, A.-M., & Papagiannakopoulos, T. Y. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0922 · Cited by 187 · see citing works
Potential Applications of NRF2 Inhibitors in Cancer Therapy
Panieri, E., & Saso, L. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8592348 · Cited by 185 · see citing works
Redox Potential of Antioxidants in Cancer Progression and Prevention
George, S., & Abrahamse, H. (2020) · Antioxidants · doi:10.3390/antiox9111156 · Cited by 180 · see citing works
Torti, S. V., & Torti, F. M. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2017 · Cited by 176 · see citing works
Targeting NRF2 and Its Downstream Processes: Opportunities and Challenges
Torrente, L., & DeNicola, G. M. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052220-104025 · Cited by 168 · see citing works
NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer
Weiss‐Sadan, T., Ge, M., Hayashi, M., Gohar, M., Yao, C.-H., de Groot, A., Harry, S. A., Carlin, A. D., Fischer, H., Shi, L., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.012 · Cited by 156 · see citing works
Aldo-Keto Reductases and Cancer Drug Resistance
Penning, T. M., Jonnalagadda, S. K., Trippier, P. C., & Rižner, T. L. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000122 · Cited by 152 · see citing works
Li, F., Aljahdali, I. A. M., Zhang, R., Nastiuk, K. L., Krolewski, J. J., & Ling, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02026-1 · Cited by 113 · see citing works
Kahroba, H., Shirmohamadi, M., Hejazi, M. S., & Samadi, N. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116986 · Cited by 96 · see citing works
Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism
Smolková, K., Mikó, E., Kovàcs, T., Leguina‐Ruzzi, A., Sipos, A., & Bai, P. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8024 · Cited by 96 · see citing works
“NRF2 addiction” in lung cancer cells and its impact on cancer therapy
Hammad, A., Namani, A., Elshaer, M., Wang, X. J., & Tang, X. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.09.016 · Cited by 88 · see citing works
Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research
Ooi, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.016 · Cited by 83 · see citing works
Self-citationOxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies
Pizzimenti, S., Ribero, S., Cucci, M. A., Grattarola, M., Monge, C., Dianzani, C., Barrera, G., & Muzio, G. (2021) · Antioxidants · doi:10.3390/antiox10121942 · Cited by 79 · see citing works
The Pleiotropic Role of the KEAP1/NRF2 Pathway in Cancer
Wu, W., & Papagiannakopoulos, T. Y. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055627 · Cited by 68 · see citing works
Mohan, T., Narasimhan, K. K. S., Ravi, D. B., Velusamy, P., Chandrasekar, N., Chakrapani, L. N., Srinivasan, A., Karthikeyan, P., Kannan, P., Tamilarasan, B., et al. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.07.037 · Cited by 66 · see citing works
Nrf2 in early vascular ageing: Calcification, senescence and therapy
Arefin, S., Buchanan, S. J., Hobson, S., Steinmetz, J. L., Alsalhi, S., Shiels, P. G., Kublickiene, K. R., & Stenvinkel, P. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.02.026 · Cited by 66 · see citing works
Recent Perspective of Lactobacillus in Reducing Oxidative Stress to Prevent Disease
Zhao, T., Wang, H., Liu, Z., Liu, Y., DeJi, Li, B., & Huang, X. (2023) · Antioxidants · doi:10.3390/antiox12030769 · Cited by 65 · see citing works
Guan, L., Nambiar, D. K., Cao, H., Viswanathan, V., Kwok, S., Hui, A. B., Hou, Y., Hildebrand, R., von Eyben, R., Holmes, B., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-1903 · Cited by 64 · see citing works
Zhang, X., Wang, Y., & Meng, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.028 · Cited by 57 · see citing works
HIF1, HSF1, and NRF2: Oxidant-Responsive Trio Raising Cellular Defenses and Engaging Immune System
Cyran, A. M., & Zhitkovich, A. (2022) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.2c00131 · Cited by 52 · see citing works
Schiavoni, V., Emanuelli, M., Milanese, G., Galosi, A. B., Pompei, V., Salvolini, E., & Campagna, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413239 · Cited by 49 · see citing works
Panieri, E., & Saso, L. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8146 · Cited by 46 · see citing works
The KEAP1-NRF2 System and Esophageal Cancer
Hirose, W., Oshikiri, H., Taguchi, K., & Yamamoto, M. P. (2022) · Cancers · doi:10.3390/cancers14194702 · Cited by 46 · see citing works
Significance of NRF2 in physiological and pathological conditions an comprehensive review
Kryszczuk, M., & Kowalczuk, O. (2022) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2022.109417 · Cited by 42 · see citing works
NRF2‐dependent stress defense in tumor antioxidant control and immune evasion
Angeli, J. P. F., & Meierjohann, S. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12946 · Cited by 43 · see citing works
Haque, E., Karim, M. R., Teeli, A. S., Śmiech, M., Leszczyński, P., Winiarczyk, D., Parvanov, E. D., Atanasov, A. G., & Taniguchi, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155378 · Cited by 39 · see citing works
Srivastava, R., Fernández-Ginés, R., Encinar, J. A., Cuadrado, A., & Wells, G. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.09.023 · Cited by 39 · see citing works
Molecular mechanisms and systemic targeting of NRF2 dysregulation in cancer
Kang, J.-S., Nam, L. B., Yoo, O.-K., & Keum, Y. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114002 · Cited by 34 · see citing works
Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma
Xie, H., Chun, F. K. ‐., Rutz, J., & Blaheta, R. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115938 · Cited by 34 · see citing works
Condello, M., & Meschini, S. (2021) · Cells · doi:10.3390/cells10123326 · Cited by 34 · see citing works
Li, M., Zhang, Z., Wang, Q., Yan, Y., & Li, B. (2022) · Nature Communications · doi:10.1038/s41467-022-32962-1 · Cited by 34 · see citing works
Mele, L. L., Vecchio, V. D., Marampon, F., Regad, T., Wagner, S., Mosca, L., Bimonte, S., Giudice, A., Liccardo, D., Prisco, C., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03056-x · Cited by 33 · see citing works
The mechanistic insights of the antioxidant Keap1-Nrf2 pathway in oncogenesis: a deadly scenario
Mukherjee, A. G., & Gopalakrishnan, A. V. (2023) · Medical Oncology · doi:10.1007/s12032-023-02124-4 · Cited by 32 · see citing works
NRF2 immunobiology in cancer: implications for immunotherapy and therapeutic targeting
Panda, H., Rowland, N. G., Krall, C. M., Bowman, B. M., Major, M. B., & Zolkind, P. (2025) · Oncogene · doi:10.1038/s41388-025-03560-4 · Cited by 35 · see citing works
Role of the KEAP1-NRF2 Axis in Renal Cell Carcinoma
Clerici, S., & Boletta, A. (2020) · Cancers · doi:10.3390/cancers12113458 · Cited by 32 · see citing works
Mitigation of Cardiovascular Disease and Toxicity through NRF2 Signalling
Roberts, J. A., Rainbow, R. D., & Sharma, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076723 · Cited by 34 · see citing works
Feng, J., Xie, L., Yu, X., Liu, C., Dong, H., Lu, W., & Kong, R. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.01.069 · Cited by 30 · see citing works
Patient-Derived Mutant Forms of NFE2L2/NRF2 Drive Aggressive Murine Hepatoblastomas
Wang, H., Lu, J. L., Mandel, J. A., Zhang, W., Schwalbe, M., Gorka, J. E., Liu, Y., Marburger, B., Wang, J., Ranganathan, S., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.02.004 · Cited by 27 · see citing works
Hasan, S. K., Jayakumar, S., Barroso, E. E., Jha, A., Catalano, G., Sandur, S. K., & Noguera, N. I. (2025) · Cells · doi:10.3390/cells14100713 · Cited by 25 · see citing works
NRF2: Master regulator of cellular homeostasis and therapeutic vulnerability in cancer
Chen, W.-T., McKee, N. W., Kuhnell, D., & Dodson, M. B. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104050 · Cited by 26 · see citing works
Kerins, M. J., Liu, P., Tian, W., Mannheim, W., Zhang, D. D., & Ooi, A. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00037-19 · Cited by 25 · see citing works
Self-citationRegulation of the immune response to contact sensitizers by Nrf2
Vallion, R., & Kerdine‐Römer, S. (2022) · Contact Dermatitis · doi:10.1111/cod.14073 · Cited by 25 · see citing works
HIF-1 and NRF2; Key Molecules for Malignant Phenotypes of Pancreatic Cancer
Hamada, S., Matsumoto, R., & Masamune, A. (2022) · Cancers · doi:10.3390/cancers14020411 · Cited by 24 · see citing works
Mehine, M. M., Ahvenainen, T., Khamaiseh, S., Härkönen, J., Reinikka, S., Heikkinen, T., Äyräväinen, A., Pakarinen, P. I., Härkki, P., Pasanen, A. M., et al. (2022) · Oncogenesis · doi:10.1038/s41389-022-00425-3 · Cited by 24 · see citing works
Chronic arsenic exposure enhances metastatic potential via NRF2-mediated upregulation of SOX9
Schmidlin, C. J., Zeng, T., Liu, P., Wei, Y., Dodson, M. B., Chapman, E., & Zhang, D. D. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115138 · Cited by 23 · see citing works
Ramisetti, S. V., Patra, T., Munirathnam, V., Sainath, J. V., Veeraiyan, D., & Namani, A. (2024) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2024.06.021 · Cited by 24 · see citing works
Sahu, M., & Jain, U. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167764 · Cited by 22 · see citing works
Emerging Therapeutic Targets in Oncologic Photodynamic Therapy.
Manda, G., Hinescu, M., Neagoe, I., Ferreira, L. F. V., Boscencu, R., Vasos, P., Basaga, S. H., & Cuadrado, A. (2019) · Current pharmaceutical design · doi:10.2174/1381612825666190122163832 · Cited by 19 · see citing works
Simov, V., Altman, M. D., Bianchi, E., DelRizzo, S., DiNunzio, E. N., Feng, G., Goldenblatt, P., Ingenito, R., Johnson, S. A., Mansueto, M. S., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113686 · Cited by 21 · see citing works
Nrf2 in Neoplastic and Non-Neoplastic Liver Diseases
Orrù, C., Giordano, S., & Columbano, A. (2020) · Cancers · doi:10.3390/cancers12102932 · Cited by 21 · see citing works
López‐Torres, C. D., Torres‐Mena, J. E., Castro‐Gil, M. P., Villa‐Treviño, S., Arellanes‐Robledo, J., del Pozo‐Yauner, L., & Pérez‐Carreón, J. I. (2022) · The Journal of Gene Medicine · doi:10.1002/jgm.3439 · Cited by 20 · see citing works
Sp1 is a substrate of Keap1 and regulates the activity of CRL4AWDR23 ubiquitin ligase toward Nrf2
Siswanto, F. M., Oguro, A., & Imaoka, S. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100704 · Cited by 19 · see citing works
Cooperation Between the NRF2 Pathway and Oncogenic β‐catenin During HCC Tumorigenesis
Savall, M., Senni, N., Lagoutte, I., Sohier, P., Dentin, R., Romagnolo, B., Perret, C., & Bossard, P. (2021) · Hepatology Communications · doi:10.1002/hep4.1746 · Cited by 20 · see citing works
Xu, Y., Hu, S., Chen, R., Xu, S., Yu, G., & Ji, L. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10731-9 · Cited by 18 · see citing works
Mechanisms of Resorcinol Antagonism of Benzo[a]pyrene-Induced Damage to Human Keratinocytes
Lee, S. E., Kwon, K., Oh, S. W., Park, S. J., Yu, E., Kim, H., Yang, S., Park, J. Y., Chung, W., Cho, J. Y., et al. (2020) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2020.083 · Cited by 18 · see citing works
Ramesh, P. S., Bovilla, V. R., Swamy, V. H., Manoli, N. N., Dasegowda, K. B., Siddegowda, S. M., Chandrashekarappa, S., Somasundara, V. M., Kabekkodu, S. P., Rajesh, R., et al. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.06.011 · Cited by 18 · see citing works
Small molecule screen identifies pyrimethamine as an inhibitor of NRF2-driven esophageal hyperplasia
Paiboonrungruang, C., Xiong, Z., Lamson, D. R., Li, Y., Bowman, B. M., Chembo, J., Huang, C. D., Li, J., Livingston, E. W., Frank, J. E., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102901 · Cited by 18 · see citing works
Differential squamous cell fates elicited by NRF2 gain of function versus KEAP1 loss of function
Takahashi, J. A., Suzuki, T., Sato, M., Nitta, S., Yaguchi, N., Muta, T., Tsuchida, K., Suda, H., Morita, M., Hamada, S., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114104 · Cited by 18 · see citing works
Orrù, C., Perra, A., Kowalik, M. A., Rizzolio, S., Puliga, E., Cabras, L., Giordano, S., & Columbano, A. (2020) · Cancers · doi:10.3390/cancers12082305 · Cited by 18 · see citing works
Hamad, S. H., Montgomery, S. A., Simon, J. M., Bowman, B. M., Spainhower, K. B., Murphy, R. M., Knudsen, E. S., Fenton, S. E., Randell, S. H., Holt, J. R., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02348-0 · Cited by 16 · see citing works
Liu, S., Liu, J., Xie, Y., Zhai, T., Hinderer, E. W., Stromberg, A. J., Vanderford, N. L., Kolesar, J., Moseley, H., Chen, L., et al. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa957 · Cited by 16 · see citing works
Lee, Y. S., Kang, J. K., Jung, E. S., & Lee, A. (2023) · Journal of Breast Cancer · doi:10.4048/jbc.2023.26.e42 · Cited by 15 · see citing works
NRF2-Driven KEAP1 Transcription in Human Lung Cancer
Tian, Y., Liu, Q., Yu, S., Chu, Q., Chen, Y., Wu, K., & Wang, L. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0108 · Cited by 15 · see citing works
Understanding the Impact of Oxidative Stress on Ovarian Cancer: Advances in Diagnosis and Treatment
Meshkovska, Y., Abramov, A., Mahira, S., & Thatikonda, S. (2024) · Future Pharmacology · doi:10.3390/futurepharmacol4030035 · Cited by 14 · see citing works
Bae, T., & Kwak, M. (2024) · Journal of Cancer Prevention · doi:10.15430/jcp.24.021 · Cited by 14 · see citing works
Banas, K. H., Rivera-Torres, N., Bialk, P. A., Yoo, B.-C., & Kmiec, E. B. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-1208 · Cited by 14 · see citing works
Chen, C., Carrillo, N. D., Chen, M., Wen, T., Awasthi, P., Anderson, R. A., & Cryns, V. L. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110367 · Cited by 13 · see citing works
NRF2 mutation enhances the immune escape of hepatocellular carcinoma by reducing STING activation
Li, C., Liang, G., Yan, K., & Wang, Y. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149536 · Cited by 13 · see citing works
Iwasaki, T., Shirota, H., Sasaki, K., Ouchi, K., Nakayama, Y., Oshikiri, H., Otsuki, A., Suzuki, T., Yamamoto, M., & Ishioka, C. (2024) · Cancer Science · doi:10.1111/cas.16355 · Cited by 12 · see citing works
Jin, X., Lou, X., Qi, H., Zheng, C., Li, B., Siwu, X., Liu, R., Lv, Q., Zhao, A., Ruan, J., et al. (2024) · Oncogenesis · doi:10.1038/s41389-024-00536-z · Cited by 12 · see citing works
Nguyen, M. T., Lee, G. J., Kim, B. R., Kim, H. J., Tak, J., Park, M. K., Kim, E. J., Kang, G.-J., Rho, S. B., Lee, H. J., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107512 · Cited by 14 · see citing works
Dysregulation of Redox Status in Urinary Bladder Cancer Patients
Reszka, E., Lesicka, M., Wieczorek, E., Jabłońska, E., Janasik, B., Stepnik, M., Konecki, T., & Jabłonowski, Z. (2020) · Cancers · doi:10.3390/cancers12051296 · Cited by 12 · see citing works
Computational analysis of protein–protein interactions of cancer drivers in renal cell carcinoma
Pei, J., Zhang, J., & Cong, Q. (2023) · FEBS Open Bio · doi:10.1002/2211-5463.13732 · Cited by 11 · see citing works
Choe, J. H., Mazambani, S., Kim, T. H., & Kim, J. (2021) · Cells · doi:10.3390/cells10030606 · Cited by 13 · see citing works
NRF2-driven redox metabolism takes center stage in cancer metabolism from an outside-in perspective
Choi, E.-J., & Jeon, S. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01224-3 · Cited by 10 · see citing works
Nrf2 induces malignant transformation of hepatic progenitor cells by inducing β-catenin expression
Fragoulis, A., Schenkel, J., Schröder, N., Brandt, E. F., Weiand, M., Neu, T., Ramadori, P., Caspers, T., Kant, S., Pufe, T., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102453 · Cited by 11 · see citing works
NRF2 Activation in Trp53;p16-deficient Mice Drives Oral Squamous Cell Carcinoma
Hamad, S. H., Sellers, R. S., Wamsley, N. T., Zolkind, P., Schrank, T. P., Major, M. B., & Weissman, B. E. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0386 · Cited by 10 · see citing works
Chen, Y., Jiao, D., He, H., Sun, H., Liu, Y., Shi, Q., Zhang, P., Li, Y., Mo, R., Gao, K., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102872 · Cited by 10 · see citing works
Nrf2 expression in pancreatic stellate cells promotes progression of cancer
Tanaka, Y., Hamada, S., Matsumoto, R., Taguchi, K., Yamamoto, M. P., & Masamune, A. (2021) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00120.2021 · Cited by 10 · see citing works
The molecular perspective on the melanoma and genome engineering of T-cells in targeting therapy
Hajibabaie, F., Abedpoor, N., Javanmard, S. H., Hasan, A., Sharifi, M., Rahimmanesh, I., Shariati, L., & Makvandi, P. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116980 · Cited by 10 · see citing works
Nrf2, A Target for Precision Oncology in Cancer Prognosis and Treatment
Ngo, H. K. C., Le, H., & Surh, Y. (2023) · Journal of Cancer Prevention · doi:10.15430/jcp.2023.28.4.131 · Cited by 9 · see citing works
Identification of novel Nrf2/Keap1 pathway mutations in pediatric acute lymphoblastic leukemia
Akın, D. F., Aktaş, S. H., Ünal, M. A., & Kankılıç, T. (2019) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2019.1682090 · Cited by 9 · see citing works
FEATURES OF REDOX REGULATION IN TUMOR CELLS
Zenkov, N. K., Kozhin, P. M., Vcherashnyaya, A. V., Мартинович, Г. Г., Kandalintseva, N. V., & Menshchikova, E. B. (2019) · Сибирский научный медицинский журнал · doi:10.15372/ssmj20190202 · Cited by 9 · see citing works
The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer
Lui, K., Cheung, K., Ng, W. W. M., Wang, Y., Au, D. W. H., & Cho, W. C. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211954 · Cited by 8 · see citing works
NRF2–KEAP1 as a redox signal-resolution circuit: Beyond the antioxidant switch
Sailis, A. B. (2026) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2026.03.005 · Cited by 8 · see citing works
Decoding the NRF2–NOTCH Crosstalk in Lung Cancer—An Update
Sparaneo, A., Torrisi, F., D’Angeli, F., Giurdanella, G., Bravaccini, S., Muscarella, L. A., & Fabrizio, F. P. (2025) · Antioxidants · doi:10.3390/antiox14060657 · Cited by 7 · see citing works
Tipping the balance: NRF2’s dual role in ferroptotic fate
de Souza, I., Teixeira, A. B. D. S., dos Santos, A. F., Angeli, J. P. F., & Rocha, C. R. R. (2026) · Oncogenesis · doi:10.1038/s41389-026-00630-4 · Cited by 7 · see citing works
Li, Y., Ladd, Z., Xiong, Z., Bui-Linh, C., Paiboonrungruang, C., Subramaniyan, B., Li, H., Wang, H., Balch, C., Shersher, D. D., et al. (2025) · Cancers · doi:10.3390/cancers17111853 · Cited by 7 · see citing works
Haque, E., Śmiech, M., Łuczyńska, K., Bouchard, M. F., Viger, R. S., Kono, H., Pierzchała, M., & Taniguchi, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105296 · Cited by 7 · see citing works
Nrf2 activation does not affect adenoma development in a mouse model of colorectal cancer
Knatko, E. V., Castro, C., Higgins, M., Zhang, Y., Honda, T., Henderson, C. J., Wolf, C. R., Griffin, J. L., & Dinkova‐Kostova, A. T. (2021) · Communications Biology · doi:10.1038/s42003-021-02552-w · Cited by 7 · see citing works
APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma
Cannataro, V. L., Kudalkar, S. N., Dasari, K., Gaffney, S. G., Lazowski, H., Jackson, L. K., Yildiz, I., Das, R. K., Rothberg, B. E. G., Anderson, K. S., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.07.004 · Cited by 7 · see citing works
- Authors
- Kerins, M. J., & Ooi, A.
- Affiliations
- University of Arizona (US)
- Corresponding author
- Ooi, Aikseng
- Venue
- Scientific Reports
- Published
- 2018-08-27
- Volume
- 8
- Issue
- 1
- Pages
- 12846-12846
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC6110754
- OpenAlex
- W2888569026
- Cited by
- 140
- References
- 67
- Citations by year
- 2026: 14 · 2025: 13 · 2024: 18 · 2023: 18 · 2022: 19 · 2021: 22 · 2020: 26 · 2019: 10
- FWCI
- 5.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UA Campus Repository (The University of Arizona) (acceptedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Science Foundation (DGE-1143953)
- U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (R21ES027920)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- Nrf2, somatic mutations, gain-of-function mutations, Keap1, mutational hotspots, protein stabilization, gene expression classifier, bladder cancer, lung cancer, uterine cancer, cancer genomics, TCGA
- MeSH terms
- Kelch-Like ECH-Associated Protein 1, Gain of Function Mutation, Humans, Neoplasms, Signal Transduction, Sequence Analysis, DNA, Computational Biology, Amino Acid Substitution, Databases, Genetic, Cell Line, Tumor, NF-E2-Related Factor 2, Protein Stability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
